Day: January 3, 2022

CLEVELAND, Jan. 03, 2022 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 am Eastern. In his presentation, Mr. Petras will provide an update on Sotera Health’s businesses. Sotera Health management, including Chief Financial Officer Scott Leffler, will participate in one-on-one meetings with investors during the conference. Investors and the general public are invited to listen to the live webcast of Mr. Petras’ presentation by accessing the link on the Sotera Health website under the...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Sara Kenkare-Mitra, Ph.D., the company’s newly-hired President and Head of Research and Development an inducement equity grant on January 3, 2022, consisting of inducement stock options to purchase an aggregate of 300,000 shares of the company’s common stock, inducement restricted stock units, or RSUs, covering an aggregate of 59,000 shares of the company’s common stock, and inducement performance stock units, or PSUs, covering an aggregate of 59,000 shares of the company’s common stock. These inducement stock options, inducement RSUs, and inducement PSUs are subject to the terms of Alector’s...

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) — Warner Music Group Corp. (the “Company”) (Nasdaq: WMG) today announced the sale of an aggregate of 8,562,500 shares of the Company’s Class A common stock (the “Offering”) by affiliates of Access Industries, LLC (the “Selling Stockholders”) to Morgan Stanley & Co. LLC, as the sole underwriter in the registered public offering of those shares. The Selling Stockholders are selling all of the shares of Class A common stock in the Offering, and the Company will not receive any proceeds from the Offering. Morgan Stanley & Co. LLC proposes to offer for sale the shares of common stock from time to time in one or more transactions on Nasdaq, in the over-the-counter market, through negotiated transactions or otherwise at a fixed price or prices, which may be changed, subject to receipt...

GREENWICH, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO) today announced that Troy Cooper has stepped down from his role as president, effective December 27, 2021. Mr. Cooper will continue working with the company as a senior advisor through June 30, 2022. “With the spin-off of GXO earlier this year, and in light of the progress we’ve made transforming XPO into a pure-play transportation company, Troy and I agreed this was a natural time for him to step down,” said Brad Jacobs, chairman and chief executive officer. “Troy’s contributions over the past decade have been invaluable, particularly his efforts driving the growth of our best-in-class truck brokerage business from its earliest days and his leadership of our European operations from 2015 to 2017. “We’re very well positioned with strong leaders...

EMERYVILLE, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the Company will be participating virtually in the upcoming 40th Annual J.P. Morgan Healthcare Conference. Berkeley Lights management is scheduled to present on Tuesday, January 11 at 12:45 p.m. Pacific Time / 3:45 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at www.berkeleylights.com. About Berkeley Lights Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional and genotypic information...

NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President, will present at the 40th Annual JP Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 PM ET. The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days. About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases....

Forty-six consecutive quarters of increased quarterly cash dividend on its common stock LITTLE ROCK, Ark., Jan. 03, 2022 (GLOBE NEWSWIRE) — Bank OZK (the “Bank”) (Nasdaq: OZK) announced its Board of Directors declared a quarterly cash dividend on the Bank’s common stock of $0.30 per share, up $0.01, or 3.45%, from the prior quarter. The common stock dividend is payable on January 21, 2022 to shareholders of record as of January 14, 2022. Bank OZK has increased its quarterly cash dividend on its common stock in each of the last forty-six quarters. The Board of Directors also declared a quarterly cash dividend of $0.32 per share on the Bank’s 4.625% Series A Non-Cumulative Perpetual Preferred Stock (“Series A Preferred Stock”) (Nasdaq: OZKAP) for the period covering November 4, 2021 through, but excluding February 15, 2022. The Series...

HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong...

STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 11:15 a.m. ET. A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara TherapeuticsCara Therapeutics is an early commercial-stage biopharmaceutical company leading a new...